The Pomp Podcast
#459: George Goldsmith on Improving Mental Health
- George Goldsmith's career arc spans technology, healthcare governance, and regulated industries, culminating in co-founding Compass Pathways to develop psilocybin therapy for depression.
- Depression affects over 300 million people worldwide; approximately 30% do not respond to traditional antidepressants, leaving roughly 100 million people with **treatment-resistant depression** suffering unnecessarily.
- Psilocybin appears to reset neural networks associated with rumination and negative thought patterns by disrupting the brain's "default mode network," offering potential relief where conventional medicines fail.
- Compass's clinical protocol involves weeks of antidepressant tapering, psychological preparation, a guided psilocybin session with therapists present, and structured follow-up debriefing to ensure safety and personalization.
- Regulation exists to protect vulnerable populations by ensuring medicines have rigorous safety and efficacy data; Compass deliberately sets the highest standards globally to enable responsible scale and reimbursement.
- The company's vision extends beyond single-dose therapy to a personalized, predictive, preventive model: understanding who benefits, predicting relapse risk, and preventing recurrence through ongoing support and data integration.